Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT07642544
NCT07642544Not yet recruitingNot Applicable

Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis: A Single-Center Real-World Cross-Sectional Retrospective Study

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1 site in 1 country120 target enrollmentStarted: June 1, 2026Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
120
Locations
1
Study OverviewStudy DesignEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

To evaluate the long-term efficacy of two maintenance treatment patterns of secukinumab-the standard maintenance group and the non-standard maintenance group-by assessing the median time to onset and incidence of secondary failure, as well as the time to regain response after dose escalation of secukinumab (including re-initiation of intensive dosing or shortening of the injection interval) in patients who experienced secondary failure.

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age ≥ 18 years, with a clinical diagnosis of moderate-to-severe plaque psoriasis.
  • •Initiated secukinumab treatment at our center between January 2020 and December 2025, and completed the standard 5-week induction period.
  • •Achieved PASI 75 response at the end of the induction period.
  • •Had a clearly defined maintenance treatment pattern (standard or non-standard), with complete treatment records and regular efficacy assessments.
  • •Complete electronic medical record data available for extraction.

Exclusion Criteria

  • •Failure to complete the induction period, or failure to achieve PASI 75 response by the end of the induction period.
  • •Irregular maintenance treatment pattern, or substantial missing data.
  • •Use of other targeted biologic agents or small molecule drugs during the maintenance period.
  • •Permanent discontinuation of treatment for non-efficacy reasons, such as pregnancy, severe infection, or malignancy.
  • •Participation in other interventional clinical trials that may confound efficacy assessment.

Investigators

Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

taoyue

MD

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Study Sites (1)

Loading locations...

Similar Trials

Not yet recruiting
Not Applicable
A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With SecukinumabHidradenitis Suppurativa
NCT07454889Novartis Pharmaceuticals34
Completed
Phase 3
Study of efficacy and safety of secukinumab in participants with moderate-severe rotator cuff tendinopathy
2022-502068-19-00Novartis Pharma AG81
Not yet recruiting
Unknown
A clinical trial to study the efficacy of two drugs ,secukinumab and adalimumab in the treatment of hidradenitis suppurativa
CTRI/2025/08/093223military hospital jaipur40
Recruiting
Phase 2
Identifying Effective and Cost-Conscious Maintenance Daratumumab DosingMultiple Myeloma
NCT07485647Eden Biltibo50
Recruiting
Phase 3
A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022)
2023-508015-23-00Merck Sharp & Dohme LLC5